Skip to main content
INDP
NASDAQ Life Sciences

Indaptus Q3 10-Q: Going-Concern Doubt Resolved, $26.6M Cash, No Active Trials

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$3.15
Mkt Cap
$483.781M
52W Low
$0.92
52W High
$5.96
52W Position info
242% above low
Off High info
47% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

INDP has more than doubled off its 52-week low of $0.92 on light trading volume (0.1× avg).

Summary

Indaptus reported Q3 2026 results with the prior going-concern doubt resolved on $26.6M cash plus $4.0M in CDs and $3.5M received in October, funding operations for at least a year. With no active clinical trials and R&D down 82%, the story now hinges on management finding a strategic transaction.


Key Events · Earnings and Guidance · INDP

  • Going-Concern Doubt Resolved

    Management states the conditions that previously raised substantial doubt about the ability to continue as a going concern have been resolved, based on $26.6M cash, $4.0M in short-term investments and $3.5M received in October 2026, funding operations for at least one year from issuance with no assumed future financing.

  • No Active Clinical Programs

    Decoy20 enrollment is discontinued, no participants remain in any study, and there are no current plans to initiate a new trial; the company is evaluating strategic alternatives including a Post-Investment Transaction (an investment in or acquisition of an operating business).

  • Q3 Loss Narrows on Cost Cuts

    Q3 2026 net loss was $1,048,778 ($0.01 per share) versus $2,975,117 ($2.98 per share) a year earlier; R&D fell 82% to $271,204 and G&A fell 24% to $864,663. Nine-month net loss was $5,384,709 versus $12,736,466.

  • $24M Placement Closed October 16

    The September 2026 private placement of 20,338,974 shares for approximately $24.0M gross closed on October 16, 2026 with all shares issued; $20.5M was received before September 30 and $3.5M in October.


Analysis · INDP · Life Sciences

The headline here is that the going-concern warning previously disclosed is now resolved: $26.6M cash plus $4.0M in certificates of deposit plus the $3.5M collected in October funds operations for at least a year from issuance, without assuming any future financing. That buys time, but there are no active clinical programs — Decoy20 enrollment is discontinued, no participants remain, and management has no plans to start a new trial — so the equity is now a bet on a strategic transaction (an investment in or acquisition of an operating business) rather than on a drug. The cost base has been cut hard to match: Q3 R&D fell 82% to $271,204 and G&A fell 24% to $864,663, shrinking the quarterly net loss to $1,048,778 from $2,975,117. The dilution already happened — 133,242,324 shares outstanding versus 2,167,324 at year-end after 111,000,000 preferred shares converted and two placements closed — and the $100M ATM remains an overhang on top of that.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, INDP was trading at $3.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $483.8M. The 52-week trading range was $0.92 to $5.96. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

INDP - Latest Insights

INDP
Sep 09, 2026, 9:45 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.11
Real-time Price: $3.15 info
Change: +$1.04 (+49%) info
Market Cap: $483.781M info
INDP
Aug 31, 2026, 9:25 AM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $1.14
Real-time Price: $3.15 info
Change: +$2.01 (+176%) info
Market Cap: $483.781M info
INDP
Aug 26, 2026, 4:35 PM EDT
Filing Type: 424B3
Importance Score:
7
Price at Filing: $1.16
Real-time Price: $3.15 info
Change: +$1.99 (+172%) info
Market Cap: $483.781M info
INDP
Aug 17, 2026, 5:00 PM EDT
Filing Type: S-3
Importance Score:
8
Price at Filing: $1.00
Real-time Price: $3.15 info
Change: +$2.15 (+215%) info
Market Cap: $483.781M info
INDP
Aug 13, 2026, 7:35 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.01
Real-time Price: $3.15 info
Change: +$2.14 (+212%) info
Market Cap: $483.781M info